Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including an extra group of candidates for cryotherapy

摘要

Background: Due to paucity of randomized clinical trials, intralesional immunotherapy has not been yet accepted as a standard therapeutic method. Objective: To examine the efficacy and safety of intralesional immunotherapy with tuberculin purified protein derivative (PPD) for treating recalcitrant wart. Methods: In this randomized, placebo-controlled, double-blind clinical trial, a total of 69 patients with recalcitrant warts received either intralesional PPD antigen (n=35) or intralesional saline (n=34) for six times at 2-week intervals. A third group of candidates for cryotherapy (n=33) was also included. The decrease in lesion size (good: complete response, intermediate: 50-99 improvement, poor: 0.05). Conclusion: Intralesional immunotherapy with PPD antigen is highly effective and safe for treating recalcitrant warts. Clinical trial registration: IRCT201407089844N3 in the Iranian Registry of Clinical Trials (IRCT).